Učitavanje...
Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
RB1 loss (RB1(null)) or MYCN amplification (MYCN(amp)) in fetal human retina causes retinoblastoma. SKP2 loss kills RB1(null) cells, but small molecule SKP2 inhibitors remain unexplored therapeutically. Whether SKP2 is synthetic lethal in MYCN(amp) retinoblastoma is unclear. SKP2 is the substrate re...
Spremljeno u:
| Izdano u: | Cell Death Discov |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026052/ https://ncbi.nlm.nih.gov/pubmed/32123578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-0237-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|